5 Stocks Insiders Love Right Now
They might need the cash for a big personal purchase such as a new house or yacht, or they might need the cash to fund a charity. Sometimes they sell as part of a planned selling program that they have put in place for diversification purposes, which allows them to sell stock in stages instead of selling all at one price.
Other times they sell because they think their stock is overvalued and the risk/reward is no longer attractive. Some even dump their own stock because they have inside knowledge that a competitor is eating their lunch and stealing market share.
But insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.
The key word in that last statement is "think." Just because a corporate insider thinks his or her stock is going to trade higher, that doesn't mean it will play out that way. Insiders can have all the conviction in the world that their stock is a buy, but if the market doesn't agree with them, the stock could end up going nowhere. Also, I say "usually" because sometimes insiders are loaned money by the company to buy their own stock. Those loans are often sweetheart deals and shouldn't be viewed as organic insider buying.
At the end of the day, its large institutional money managers running big mutual funds and hedge funds that drive stock prices, not insiders. That said, many of these savvy stock operators will follow insider buying activity when they agree with the insider that the stock is undervalued and has upside potential. This is why it's so important to always be monitoring insider activity, but it's twice as important to make sure the trend of the stock coincides with the insider buying.
Recently, a number of companies' corporate insiders have bought large amounts of stock. These insiders are finding some value in the market, which warrants a closer look at these stocks. Here's a look at several stocks whose insiders have been doing some big buying per SEC filings.
Key insiders have been doing some big buying in Opko Health (OPK) , a pharmaceutical and diagnostics company. It is focused on developing a range of solutions, including molecular diagnostics tests, pharmaceuticals and vaccines. This stock has done nothing so far in 2012 since shares are virtually flat on the year.
Opko Health has a market cap of $1.39 billion and an enterprise value of $1.31 billion. This stock trades at a premium valuation, with a price-to-sales of 32.27 and a price-to-book of 13.51. Its estimated growth rate for this year is -50%, and for next year it's pegged at -16.7%. This is a cash-rich company, since the total cash position on its balance sheet is $87.42 million and its total debt is $12.55 million.